Benchtop validation of a low-cost wearable triaxial accelerometer
Clinical Snapshot
PICO Framework
| P — Population | Laboratory bench-test conditions using 49 units of a newly developed low-cost triaxial accelerometer (sensor under test, SUT); no human participants were enrolled as test subjects — the study is a methodological device validation |
| I — Intervention | Low-cost triaxial accelerometer (sensor under test, SUT; approximately USD 60) measuring linear acceleration across three axes (mediolateral x, vertical y, anteroposterior z) |
| C — Comparator | Commercial reference sensor (RS): Physilog®5 (GaitUp, Lausanne, Switzerland; >USD 1,000) — a widely used, validated inertial measurement unit |
| O — Outcomes | Concurrent validity of the SUT versus the RS assessed via root mean squared error (RMSE), mean absolute error (MAE), Bland-Altman bias and limits of agreement, visual waveform overlap, and near-unity correlation coefficients across all three axes |
Bottom Line
This benchtop validation study demonstrates that a low-cost (~USD 60) triaxial accelerometer shows strong measurement agreement with a validated commercial reference sensor (Physilog®5) under controlled laboratory conditions, particularly along the mediolateral and vertical axes. The anteroposterior axis performed less consistently, with approximately 9% greater RMSE and wider Bland-Altman limits of agreement — a clinically relevant finding given the importance of this axis for forward-fall and gait-cycle detection. Critically, this is a device-level benchtop study only: no human participants were tested, no fall-detection diagnostic accuracy data are presented, and real-world ambulatory performance remains entirely uncharacterised. The study design precludes assessment of spectrum bias, clinical utility, or impact on patient management. For Australian clinicians and researchers, this work represents a promising early-stage proof of concept for scalable, low-cost motion monitoring — particularly relevant to falls prevention programs in aged care and community settings — but substantial further validation in representative clinical populations is required before any clinical or regulatory application can be considered. The device should not be used for individual patient fall-risk assessment at this stage.
Key Findings
P Value: Not reported
Effect Size: RMSE values were highly similar between x (mediolateral) and y (vertical) axes (<3.2% difference between SUT and RS); z-axis (anteroposterior) showed moderately larger errors (~9% difference). Bland-Altman analysis confirmed minimal bias and narrow limits of agreement for x and y axes; greater variability on z-axis with no evidence of substantial systematic deviation. Near-unity correlations across all axes.
Primary Outcome: Concurrent validity of the low-cost SUT triaxial accelerometer compared with the Physilog®5 reference sensor across three axes under controlled benchtop conditions
Nnt Or Sensitivity: Sensitivity and specificity not applicable to this measurement agreement study. Key agreement metrics: RMSE <3.2% difference (x, y axes); ~9% difference (z-axis); MAE similar for x and y axes, slightly higher for z-axis; Bland-Altman bias described as minimal for x and y, greater variability for z
Confidence Interval: Not explicitly reported in the abstract for bias estimates; Bland-Altman limits of agreement serve as the primary precision metric
Clinical Application
The device's low cost (~USD 60 versus >USD 1,000 for the Physilog®5) represents a significant advantage for scalable deployment in community health programs, low-resource settings, and large-scale research studies. However, feasibility in clinical practice requires demonstration of real-world validity, user acceptability, data transmission reliability, and integration with clinical workflows — none of which have been assessed. Falls prevention is a national health priority in Australia, with the RACGP and the Australian Commission on Safety and Quality in Health Care (ACSQHC) recommending multifactorial falls risk assessment for older adults. Wearable accelerometers have potential utility within community-based falls prevention programs and residential aged care settings. However, the TGA would require clinical-grade validation data before any such device could be marketed as a medical device for fall detection in Australia. The PBS does not currently subsidise wearable fall-detection technology. This device remains at a pre-clinical validation stage and is not ready for TGA submission or clinical deployment. Future studies should include Australian community-dwelling older adults to assess real-world performance in this population. At this stage, applicable only to laboratory or research settings requiring low-cost triaxial accelerometry under controlled conditions. The intended clinical population — older adults at risk of falls requiring ambulatory monitoring — has not been studied. Clinicians should not yet deploy this device for individual patient fall-risk assessment.
Abstract
Wearable inertial sensors have become a cornerstone technology for detecting fall-related events, such as tripping while walking, in older adults. However, low-cost devices must undergo rigorous validation to ensure fidelity and stability in measurement. This study aimed to evaluate the concurrent validity of a newly developed, low-cost triaxial accelerometer by comparing its linear acceleration measurements with those obtained from a widely used commercial reference sensor (RS). A methodological validation study was conducted to assess the accuracy and precision of the proposed accelerometer. Triaxial linear acceleration data were simultaneously collected from the new device (sensor under test, SUT) and a commercial RS (Physilog®5, GaitUp, Lausanne, Switzerland). Measurements were obtained across three independent axes from 49 SUT units, with three repeated trials performed for each axis. The RS exhibited a more negative mean bias on the mediolateral (x) axis and a slightly larger mean bias on the vertical (y) axis. The SUT showed a greater mean bias (offset) on the anteroposterior (z) axis. Root mean squared error values were highly similar between thexandyaxes (<3.2% difference), while thez-axis presented moderately larger errors (∼9%). Mean absolute error was similar in thexandyaxes, whereas thez-axis was slightly higher. Visual waveform comparisons demonstrated strong overlap in mean time-series profiles, and near-unity correlations indicated high correspondence in signal variation. Bland-Altman analysis confirmed minimal bias and narrow limits of agreement for thexandyaxes, with greater variability observed along thezaxis, but no evidence of substantial systematic deviation. Overall, the low-cost accelerometer (∼60 USD) showed strong agreement with the commercial reference device (>1 000 USD), supporting its validity for three-dimensional linear acceleration measurement under controlled laboratory conditions. This low-cost device represents a promising solution for scalable motion monitoring and fall-related event detection.
References
- 1.Silva, C. F. E., Leal, I. D. S., de Melo, P. R. V., Silva, M. A., Caldas, R. R., Buarque, F., & Trombini-Souza, F. (2026). Benchtop validation of a low-cost wearable triaxial accelerometer. Biomedical Physics & Engineering Express. https://doi.org/10.1088/2057-1976/ae866e
Related Research
Sleep medicine
Concordance of wearable device sleep metrics with patient-reported sleep quality: A systematic review
3 Aug 2026
Sleep medicine reviews
Machine and deep learning in REM sleep behavior disorder: a scoping review and analysis of reporting quality
3 Aug 2026
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Efficacy and safety of fecal microbiota transplantation in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment
1 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service